Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Intensive radiographic and biomarker surveillance in stage II and III colorectal cancer.
Fora A, Patta A, Attwood K, Wilding G, Fakih M.
Oncology. 2012;82(1):41-7. Epub 2012 Jan 26.
Related citations
Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study.
Barret M, Malka D, Aparicio T, Dalban C, Locher C, Sabate JM, Louafi S, Mansourbakht T, Bonnetain F, Attar A, Taieb J.
Oncology. 2011;81(5-6):395-402. Epub 2012 Jan 20.
Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients.
Königsberg R, Hulla W, Klimpfinger M, Reiner-Concin A, Steininger T, Büchler W, Terkola R, Dittrich C.
Oncology. 2011;81(5-6):359-64. Epub 2012 Jan 13.
Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, Kim NK, Rha SY.
Oncology. 2011;81(3-4):175-83. Epub 2011 Nov 3.
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Shitara K, Matsuo K, Kondo C, Takahari D, Ura T, Inaba Y, Yamaura H, Sato Y, Kato M, Kanemitsu Y, Komori K, Ishiguro S, Sano T, Shimizu Y, Muro K.
Oncology. 2011;81(3-4):167-74. Epub 2011 Nov 1.
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Boisen MK, Johansen JS, Larsen O, Jensen BV.
Oncology. 2011;80(1-2):138-9. Epub 2011 Jun 15. No abstract available.
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Kabbinavar F, Kozloff M.
Oncology. 2011;80(1-2):135-7; author reply 140-1. Epub 2011 Jun 15. No abstract available.
FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Nozawa H, Kitayama J, Sunami E, Saito S, Kanazawa T, Kazama S, Yazawa K, Kawai K, Mori K, Nagawa H.
Oncology. 2011;80(1-2):84-91. Epub 2011 Jun 13.
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M.
Oncology. 2011;80(1-2):70-5. Epub 2011 Jun 9.
BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer.
Brunetto de Farias C, Rosemberg DB, Heinen TE, Koehler-Santos P, Abujamra AL, Kapczinski F, Brunetto AL, Ashton-Prolla P, Meurer L, Reis Bogo M, Damin DC, Schwartsmann G, Roesler R.
Oncology. 2010;79(5-6):430-9. Epub 2011 Apr 8.
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E.
Oncology. 2010;79(5-6):415-22. Epub 2011 Apr 7.
Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer.
Grothey A.
Oncology. 2010;79(5-6):389-99. Epub 2011 Mar 25. Review.
Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer.
Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T.
Oncology. 2010;79(3-4):313-20. Epub 2011 Mar 17.
Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, Lee SJ, Jeon SW, Park JS, Park JY, Choi GS.
Oncology. 2010;79(3-4):278-82. Epub 2011 Mar 16.
Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer.
Manzoni M, Rovati B, Ronzoni M, Loupakis F, Mariucci S, Ricci V, Gattoni E, Salvatore L, Tinelli C, Villa E, Danova M.
Oncology. 2010;79(3-4):187-96. Epub 2011 Feb 28.
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Dominguez S, Faroux R, Florentin V, Douillard JY.
Oncology. 2010;79(3-4):174-80. Epub 2011 Feb 28.
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Zhang J, Stevens MF, Hummersone M, Madhusudan S, Laughton CA, Bradshaw TD.
Oncology. 2011;80(3-4):195-207. Epub 2011 Jul 1.
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC.
Oncology. 2010;79(1-2):13-26. Epub 2010 Nov 3. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on